The National Institutes of Health (NIH) announced that the Operation Warp Speed sponsored COVID-19 vaccine, Moderna’s mRNA-1273, has begun Phase 3 clinical trial. The trial is expected to enroll 30,000 adult volunteers.
The NIH notes that Moderna is leading the trial as the regulatory sponsor, and National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) are providing funding for the trial. This is the first vaccine efficacy trial implemented under Operation Warp Speed.
Additionally, the NIH Coronavirus Prevention Network (CoVPN) will assist in coordinating the clinical trial across 24 clinical research sites.